Regulatory – Alligator Bioscience

2023-01-02

Regulatory

Alligator Bioscience Announces Positive Interim Results from Mitazalimab OPTIMIZE-1 Phase 2 Trial in Pancreatic Cancer Exceeding 50% Objective Response Rate

52% Objective Response Rate in pre-planned interim efficacy analysis of mitazalimab combined with mFOLFIRINOX in 1st line metastatic pancrea ...

2023-01-02

Regulatory

The second project aims to develop a bispecific antibody with potential applications in solid tumors Alligator and Orion each to provide val ...

2022-07-12

Regulatory

· Mitazalimab OPTIMIZE-1 interim data and ATOR-1017 Phase 1 on track to readout in H2 2022 · Decision to leverage OPTIMIZE-1 interim data be ...

2022-04-27

Regulatory

A Quarter of Advancements for Alligator’s Key Assets “Q1 2022 was marked by many important advancements. We made progress with our key ass ...

2022-04-05

Regulatory

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedis ...

2022-03-31

Regulatory

During the month of March, the number of shares and votes in Alligator Bioscience AB have increased due to directed issue and repurchase of ...

2022-03-22

Regulatory

Pursuant to the authorization granted by the annual general meeting on 1 June 2021, the board of directors of Alligator Bioscience AB (”Alli ...

2022-03-22

Regulatory

Lund, Sweden, March 22, 2022 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the Annual Report for 2021 has been publi ...

2022-03-11

Regulatory

REGULATORY 11 March 2022 Ahead of the Annual General Meeting in Alligator Bioscience AB on May 5, 2022, the Nomination Committee announces i ...